Denali Therapeutics Inc. (DNLI) Tops Q4 EPS by 4c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.75), $0.04 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $10.28 million versus the consensus estimate of $13.12 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance
• Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates